Abstract
Background/Aims/Objectives: We studied the detection rate of prostate cancer (PCa) among Korean men with a prostate-specific antigen (PSA) level of less than 4.0 ng/mL. Methods: A total of 1,680 men with PSA ≤4 ng/mL had a prostate biopsy from January 2004 to December 2014. The differences in clinical factors were analyzed and their independent predictive implications were evaluated. Results: PCa was diagnosed in 331 (19.6%) and 99 of these 331 cancers (14.9%) had a Gleason score of 7 or higher. The detection rate of PCa increased from 6.67% (≤0.5 ng/mL) to 20.36% (3.01-3.9 ng/mL). There were significant differences in age 65.7 vs. 62.1 years, prostate volume 33.4 vs. 38.2 g, PSA density 0.10 vs. 0.08 ng/mL/mL between men with and without PCa. On multivariable analysis, age and prostate volume were the best independent discriminative parameters. When comparing PCa patients with a Gleason score less than 6 to those with a 7 or higher, patients with a Gleason score 7 or higher were older (67.2 vs. 64.8 years). Conclusions: Even when the PSA level is less than 4 ng/mL, PCas, including high-grade cancers, were detected in a significant number of men. In this group, patients with PCa were older and had a smaller prostate volume and high-grade cancers were detected more frequently in older cancer patients.
References
1.
Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al: Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-1291.
2.
Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T: The Japanese guideline for prostate cancer screening. Jpn J Clin Oncol 2009;39:339-351.
3.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
4.
Schmid HP, Riesen W, Prikler L: Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004;50:71-78.
5.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
6.
Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325:740.
7.
Lu-Yao GL, McLerran D, Wasson J, Wennberg JE: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993;269:2633-2636.
8.
Hong SJ, Ko WJ, Kim SI, Chung BH: Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol 2003;44:94-99; discussion 99-100.
9.
Potosky A, Miller B, Albertsen PC, Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-552.
10.
Ries L, Eisner M, Clegg L, et al: SEER Cancer Statistics Review, 1973-1997. Bethesda, National Cancer Institute, 2000.
11.
Kim M, Lee HE, Oh SJ: Technical aspects of holmium laser enucleation of the prostate for benign prostatic hyperplasia. Korean J Urol 2013;54:570-579.
12.
Thompson IM, Ernst JJ, Gangai MP, Spence CR: Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984;132:690-692.
13.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-1547.
14.
Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
15.
Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147(3 pt 2):841-845.
16.
Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
17.
Carvalhal GF, Smith DS, Mager DE, et al: Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999;161:835-839.
18.
Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, et al: Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-812.
19.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
20.
Kim HW, Ko YH, Kang SH, Lee JG: Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml. Korean J Urol 2011;52:166-171.
21.
Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y: Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population. Urology 2004;63:727-731.
22.
Choi SK, Song C, Shim M, Min GE, Park J, Jeong IG, Hong JH, Kim CS, Ahn H: Prevalence of high-grade or insignificant prostate cancer in Korean men with prostate-specific antigen levels of 3.0-4.0 ng/mL. Urology 2015;85:610-615.
23.
Park HK, Hong SK, Byun SS, Lee SE: Comparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0ng/mL and the patients with a serum PSA level in the range 4.1 to 10.0ng/mL. Korean J Urol 2006;47:358-361.
24.
Kwon T, Jeong IG, Hong JH, Ahn H, Kim CS: Analysis of the clinicopathologic characteristics of men with prostate cancer undergoing radical prostatectomy in the prostate-specific antigen range of less than 4 ng/ml. Korean J Urol 2009;50:320-326.
25.
Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA: Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL. Urology 2005;66:803-807.
26.
Dantanarayana ND, Hossack T, Cozzi P, Brooks A, Lau H, Delprado W, Patel MI: Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia. BMC Urol 2015;15:124.
27.
Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Recker F, Kwiatkowski M: Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening. Urol Int 2015;94:330-336.
28.
Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011;29:1736-1743.
29.
Kendal WS: Age bias in time from diagnosis comparisons of prostate cancer treatment. Am J Clin Oncol 2016, Epub ahead of print.
30.
Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N: Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 2007;69:103-107.
31.
Stamey TA, Johnstone IM, McNeal JE, et al: Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002;167:103-111.
32.
Chen ME, Troncoso P, Johnston D, et al: Prostate cancer detection: relationship to prostate size. Urology 1999;53:764-768.
33.
Drazer MW, Huo D, Eggener SE: National prostate cancer screening rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416-2423.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
